News|Articles|November 17, 2026

FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLC

Author(s)Riley Kandel
Fact checked by: Ashling Wahner
Listen
0:00 / 0:00

Key Takeaways

  • FDA accelerated approval covers ALK-positive NSCLC after alectinib, or after ≥2 prior ALK TKIs plus platinum chemotherapy in unresectable locally advanced or metastatic disease.
  • ALKOVE-1 post-alectinib cohort (n=67) demonstrated 49% ORR, with 76% of responders maintaining DOR ≥6 months and 52% maintaining DOR ≥12 months.
SHOW MORE

The FDA has approved neladalkib for previously treated, ALK-positive, locally adanced or metastatic non-small cell lung cancer.

The FDA has granted accelerated approval to neladalkib (Nelkarmi) for patients with locally advanced or metastatic ALK-positive non–small cell lung cancer (NSCLC) who have been previously treated in the unresectable locally advanced or metastatic setting with either a prior ALK-directed TKI consisting of alectinib (Alecensa), or 2 or more prior ALK-directed TKIs and platinum-based chemotherapy.1

The approval was supported by data from the phase 1/2 ALKOVE-1 study (NCT05384626) where patients who received a prior ALK-directed TKI consisting of alectinib (n = 67) achieved an overall response rate (ORR) of 49% (95% CI, 37%-62%), alongside 76% of patients having a duration of response (DOR) that was 6 months or longer and 52% had a DOR of 12 months or longer.

Moreover, patients who received two or more prior ALK TKIs and platinum-based chemotherapy (n = 155), achieved an ORR of 32% (95% CI, 24%-40%), with 69% and 51% achieving DORs of at least 6 and 12 months, respectively.

Before the approval, the FDA had granted neladalkib breakthrough therapy designation for patients with locally advanced or metastatic ALK-positive NSCLC previously treated with 2 or more ALK TKIs, as well as orphan drug designation for ALK-positive NSCLC.2 In May 2026, the agency accepted the new drug application for neladalkib with priority review and set a target action date of November 27, 2026.3

How was the ALKOVE-1 trial designed?

The global, first-in-human, open-labe trial is evaluating neladalkib in patients with advanced ALK-positive NSCLC and other ALK-positive solid tumors.4

The phase 1 portion of the study evaluated neladalkib at doses from 15 mg to 200 mg once daily in patients with advanced ALK-positive solid tumors and established a recommended phase 2 dose of 150 mg once daily.

In the phase 2 portion, patients with ALK-positive NSCLC were enrolled into cohorts based on prior treatment: 1 prior second-generation ALK TKI with 0 to 2 prior lines of chemotherapy or immunotherapy, 2 or 3 prior ALK TKIs of any generation with 0 to 2 prior lines of chemotherapy or immunotherapy, lorlatinib (Lorbrena) as the only prior ALK TKI with up to 1 prior line of chemotherapy or immunotherapy, no prior ALK TKI with up to 1 prior line of chemotherapy or immunotherapy, and patients not eligible for the other cohorts. A separate cohort enrolled patients with other ALK-positive solid tumors.

The primary end point of the phase 2 portion was ORR by blinded independent central review (BICR) per RECIST 1.1 criteria. Secondary end points included DOR, time to response, progression-free survival (PFS), overall survival, intracranial activity, safety, tolerability, and pharmacokinetics.

In the efficacy-evaluable population (n = 253), patients had a median age of 56 years (range, 24-83), 57% of patients were female, 66% had no history of smoking, and 64% had an ECOG performance status of 1. Additionally, at baseline, 40% of patients had central nervous system (CNS) metastases, 36% had a secondary ALK mutation, 19% had an ALK G1202R mutation, and 17% had 2 or more ALK mutations. Patients had received a median of 3 prior anticancer therapies (range, 1-11), including chemotherapy in 51% of patients, alectinib in 87%, and lorlatinib in 75%.

What additional efficacy data were reported neladalkib in NSCLC?

Previous data from the study presented at the 2026 ASCO Annual Meeting showed an ORR of 31% (95% CI, 26%-37%) among all ALK TKI–pretreated patients (n = 253), including a complete response (CR) rate of 2%. The ORR was 46% (95% CI, 33%-59%) in lorlatinib-naive patients (n = 63) and 26% (95% CI, 20%-33%) in lorlatinib-experienced patients (n = 190).

With a median follow-up of 11.3 months, the median DOR was not reached (95% CI, 14.5-not estimable) among all responders (n = 77), and 64% (95% CI, 51%-75%) of responders had a DOR of at least 12 months. The 12-month DOR rate was 80% (95% CI, 58%-91%) among lorlatinib-naive responders (n = 29), and the median DOR was 17.6 months (95% CI, 6.9-not estimable) among lorlatinib-experienced responders (n = 48).

The median PFS was 5.7 months (95% CI, 4.4-6.5) in the overall ALK TKI–pretreated population, 14.5 months (95% CI, 4.8-not estimable) in lorlatinib-naive patients, and 4.6 months (95% CI, 2.8-6.2) in lorlatinib-experienced patients.

What is the safety profile of neladalkib?

Treatment-emergent adverse effects (TEAEs) led to dose reductions in 17% of patients (n = 656), most commonly for increased alanine aminotransferase (ALT; 10%) and aspartate aminotransferase (AST; 8%) levels.

The most common TEAEs were increased ALT (any-grade, 47%; grade 3, 20%), increased AST (44%; 16%), constipation (28%; 0.2%), dysgeusia (23%), peripheral edema (18%; 0.3%), cough (16%; 0.5%), and nausea (16%; 0.8%).

Investigators also reported that most transaminase elevations were asymptomatic laboratory abnormalities that were low grade, transient, and reversible with dose interruptions or reductions, and that the overall safety profile was consistent with avoiding TRK-related neurotoxicities.2

What are the next steps for neladalkib?

Neladalkib is being compared with alectinib in patients with TKI-naive advanced ALK-positive NSCLC in the ongoing phase 3 ALKAZAR trial (NCT06765109), which incorporates enhanced monitoring and prompt dose interventions for transaminase elevations in its protocol.4

References

  1. FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer. News release. FDA. November 17, 2026. Accessed November 17, 2026. https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-neladalkib-previously-treated-locally-advanced-or-metastatic-alk
  2. Nuvalent announces key program and business updates, strengthening foundation for global leadership in ROS1- and ALK-positive NSCLC. News release. Nuvalent, Inc. May 27, 2026. Accessed November 17, 2026. https://www.prnewswire.com/news-releases/nuvalent-announces-key-program-and-business-updates-strengthening-foundation-for-global-leadership-in-ros1--and-alk-positive-nsclc-302782393.html
  3. Doherty K. FDA grants priority review to neladalkib for TKI-pretreated ALK+ NSCLC. OncLive. May 27, 2026. Accessed November 17, 2026. https://www.onclive.com/view/fda-grants-priority-review-to-neladalkib-for-tki-pretreated-alk-nsclc
  4. Lin JJ, Felip E, Cho BC, et al. ALKOVE-1: efficacy and safety of neladalkib in patients with advanced ALK+ NSCLC. J Clin Oncol. 2026;44(suppl 16):8503. doi:10.1200/JCO.2026.44.16_suppl.8503

Related to this article